![]() | |
Clinical data | |
---|---|
Trade names | Maxair |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a601096 |
Pregnancy category |
|
Routes of administration | Inhalational (MDI) |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChemCID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C12H20N2O3 |
Molar mass | 240.303 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
![]() ![]() |
Pirbuterol (trade nameMaxair) is a short-actingβ2 adrenoreceptor agonist withbronchodilating action used in the treatment ofasthma, available (as pirbuterol acetate) as a breath-activatedmetered-dose inhaler.
It was patented in 1971 and came into medical use in 1983.[1]
Pirbuterol is used in asthma for reversal of acutebronchospasm, and also as a maintenance medication to prevent future attacks. It should be used in patients 12 years of age and older with or without concurrenttheophylline and/or inhaledcorticosteroid.[2][3]
After inhalation of doses up to 800μg (twice the maximum recommended dose) systemic blood levels of pirbuterol are below the limit of assay sensitivity (2–5 ng/ml). A mean of 51% of the dose is recovered in urine as pirbuterol plus its sulfate conjugate following administration by aerosol. Pirbuterol is not metabolized bycatechol-O-methyltransferase. The plasma half-life measured after oral administration is about two hours.[2]
![]() | Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byexpanding it. |